Completed Epilepsy trials in Romania: Trial Insights

Filters: Condition: Epilepsy Status: Completed Country / region: Romania Clear all

26 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2004	1
2005	2
2006	1
2007	2
2008	1
2010	1
2011	4
2012	3
2013	2
2014	2
2015	3
2016	1
2020	1
2021	1
2022	1

Trials by status
Category	Trials
Completed	26

Top lead sponsors
Category	Trials
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	6
UCB Pharma	5
Bial - Portela C S.A.	4
UCB BIOSCIENCES, Inc.	4
UCB Biopharma SRL	3
UCB BIOSCIENCES GmbH	2
Eisai Inc.	1
UCB Biopharma S.P.R.L.	1

Top conditions
Category	Trials
Epilepsy	26
Seizures	6
Epilepsies, Partial	3
Epilepsy, Absence	2

Trials

Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy NCT05109234Phase 3CompletedUCB Biopharma SRLStarted 2022
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy NCT04666610Phase 3CompletedUCB Biopharma SRLStarted 2021
A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment NCT04627285Phase 3CompletedUCB Biopharma SRLStarted 2020
A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994 NCT02582866Phase 3CompletedUCB Biopharma S.P.R.L.Started 2016
Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures NCT02408549Phase 3CompletedUCB BIOSCIENCES, Inc.Started 2015
Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures NCT02477839Phase 3CompletedUCB BIOSCIENCES, Inc.Started 2015
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications NCT02408523Phase 3CompletedUCB BIOSCIENCES, Inc.Started 2015
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures. NCT02072824Phase 3CompletedPfizer's Upjohn has merged with Mylan to form Viatris Inc.Started 2014
A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures NCT01964560Phase 3CompletedUCB BIOSCIENCES, Inc.Started 2014
Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures NCT01921205Phase 3CompletedUCB PharmaStarted 2013
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures. NCT01747915Phase 3CompletedPfizer's Upjohn has merged with Mylan to form Viatris Inc.Started 2013
Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours NCT02021461Phase 2CompletedBial - Portela C S.A.Started 2012
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older NCT01465997Phase 3CompletedUCB BIOSCIENCES GmbHStarted 2012
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures NCT01463306Phase 3CompletedPfizer's Upjohn has merged with Mylan to form Viatris Inc.Started 2012
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam NCT01484977Phase 3CompletedUCB PharmaStarted 2011
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years NCT01389596Phase 3CompletedPfizer's Upjohn has merged with Mylan to form Viatris Inc.Started 2011
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older NCT01243177Phase 3CompletedUCB BIOSCIENCES GmbHStarted 2011
Once-A-Day Pregabalin For Partial Seizures NCT01262677Phase 3CompletedPfizer's Upjohn has merged with Mylan to form Viatris Inc.Started 2011
Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients NCT01422720Phase 3CompletedBial - Portela C S.A.Started 2010
Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures NCT00735397Phase 3CompletedEisai Inc.Started 2008
Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children NCT00988156Phase 3CompletedBial - Portela C S.A.Started 2007
Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy Patients NCT00394927ObservationalCompletedUCB PharmaStarted 2007
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy NCT00280059Phase 3CompletedPfizer's Upjohn has merged with Mylan to form Viatris Inc.Started 2006
Pharmacokinetics, Efficacy and Tolerability of BIA 2-093 NCT02170064Phase 2CompletedBial - Portela C S.A.Started 2005
Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy NCT00175903Phase 3CompletedUCB PharmaStarted 2005

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory